Roundtable
Advertisement
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo.
The panel focuses on CN, oligometastatic disease treatment, and advancements in systemic therapies over the past few decades.
The panel explores our understanding of nccRCC, including classification, molecular distinctions, and prognostic criteria.
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting.
The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens.
The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr.
The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs.
The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC.
The panel dissects a longitudinal follow-up of a multicenter study of UGN-101 as well as other 2024 AUA meeting data.
The panel considers how to best treat patients with low-grade UTUC who experience disease recurrence post-surgery.
The panel highlights nephron-sparing approaches as well as current treatment pathways for low-grade UTUC.
The panel provides a disease state overview of low-grade UTUC, including considerations for diagnosis, staging, and grading.
The panel engages in a discussion related to risk stratification in UTUC, including identification of high-risk patients.
The panel shared their excitement for the road ahead in kidney cancer.
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
The panel discussed the impact of a subcutaneous formulation of nivolumab.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.